FDA submission
Enzo Biochem Q1 2022 Revenues Down 8 Percent
The company said its life sciences revenues fell 9 percent from Q1 2021 because of ongoing COVID-19-related shutdowns in Europe, among other reasons.
Geneoscopy Closes $105M Series B Financing Round
The company said it will use the funds in part to support a study of ColonoSight, its multi-target stool RNA test for colorectal screening.
German MDx Firm Mainz Biomed Raises $10M in IPO, Begins Trading on Nasdaq
The company, which has been developing a colorectal cancer diagnostic called ColoAlert, priced its IPO last week, offering 2 million shares at $5 per share.
Arquer Dx Developing Urine-Based Protein Biomarker Tests to Detect Bladder, Endometrial Cancers
Premium
Arquer's assays use mouse monoclonal antibodies to detect levels of MCM5 proteins in cells exfoliated into urine to detect either bladder or endometrial cancers.
Tempus Submits PMA Application for Tumor Profiling Assay to FDA
The firm has submitted companion diagnostic and tumor profiling, and MSI status claims using DNA from FFPE tumor tissue and matched normal specimens.